News
Comprehensive coverage on the latest pharmaceutical regulatory update and industry activities in China.
Hot topic
REGULATION
Law & Regulation
Guideline
Reference Listed Drug (RLD)
MAH
Pharmacovigilance
Marketing Approval
CMC
Bioequivalence (BE)
Post-market
Generic Drug
Biosimilar
Cancer
New Drug
Monthly Recap: China Pharmaceutical Regulatory Updates | April 2022
Check out China's pharmaceutical regulation updates April 2022: China NMPA releases Pharmacovigilance Inspection Guidelines...
May 05, 2022
INDUSTRY
Multinational Pharma Companies Record Sales Growth in 2021
Johnson & Johnson ranks the first with global sales of 93.77 billion USD.
Pfizer has the most rapid growth in global sales, zooming up by 95% to 81.3 billion USD.
AstraZeneca is the largest foreign pharma company regarding its 5.99 billion USD sales in China.
MSD records the most vigorous sales growth in China of 60%, bringing the sales to 4.26 billion USD.
Mar 18, 2022
REGULATION
Law & Regulation
Guideline
Reference Listed Drug (RLD)
Marketing Approval
Clinical Trial
Generic Drug
Biosimilar
New Drug
Monthly Recap: China Pharmaceutical Regulatory Updates | January 2022
1. China Pilots Online Sales of Prescription Drugs in Shenzhen;
2. National Insulin Procurement to Start in May;
3. China NMPA Grants Two Rx-to-OTC Switches;
4. China NMPA Releases the 50th Batch of Reference Listed Drugs;
5. China NMPA Approves 221 Medical Devices;
6. China NMPA Issues Three Industry Standards for Medical Devices;
7. Pharmaceutical Guidelines.
Feb 10, 2022
INDUSTRY
Marketing Approval
Priority Review
Innovative Drug
Generic Drug
Biological Product
Biosimilar
Drug Registration
New Drug
Monthly Report: New Drug Approvals in China | Oct. 2021
In Oct. 2021, China's NMPA granted marketing authorization approvals to 11 new drugs, including Takeda's VOCINTI and Sanofi's Clopidogrel Bisulfate and Aspirin Tablets.
Nov 08, 2021
INDUSTRY
Marketing Approval
Innovative Drug
Generic Drug
Biological Product
Biosimilar
Drug Registration
New Drug
Monthly Report: New Drug Approvals in China | Sept. 2021
In Sept. 2021, China's NMPA granted 13 new drug approvals, including for Sanofi-Aventis Groupe's Dupilumab Injection and Merck's Pembrolizumab Injection.
Oct 25, 2021
Most Popular
- Monthly Report: New Drug Approvals in China | February 2024
- Monthly Recap: China Pharmaceutical Regulatory Updates | February 2024
- Monthly Report: New Drug Approvals in China | March 2024
- Monthly Recap: China Pharmaceutical Regulatory Updates | March 2024
- China Consults on Self-Evaluation Report Guidance for Generic Drug Registration